ClinicalTrials.gg
RecruitingNCT05669027NINRUpdated Dec 17, 2025

Mobile Neurofeedback for Low Back Pain

An interventional study of Neurofeedback and Sham (Placebo Control) in Chronic Low Back Pain, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Pain by Duke University — 8 open to participants now, 8 under way, none of them phase 3. Pain · Duke University.

Planned enrollment
13th of 46
150 · median 64
Started
2023
with 7 others
No phase
29 of 51
6 open now
Registered
41st of 51
by date

Among the 51 studies in Pain by Duke University, this one is the 13th largest by planned enrollment of the 46 interventional ones that give a count, is one of 8 that started in 2023, is one of 29 with no phase, and was the 41st registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

8 of the 51 studies in Pain by Duke University are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Pain by Duke University, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about improving the quality of treatments for people who have chronic low back pain. Participants will complete interviews with Duke researchers at four different time points: the beginning of the study, at 3 months, at 6 months, and at 9 months. Participants will be asked to use a mobile app and a headset that are designed to train the brain to be more relaxed. Participants will use the mobile app for 10 minutes at a time, four times a week for three months. The study team will also check in with participants about app use six times throughout the study, via phone or video conference.

Read the detailed description

This is a double-blind randomized controlled trial to test effects of mHealth mobile neurofeedback on the outcomes of pain, enrolling 150 adult participants (18 years of age or older) with chronic low backpain. Participants will be scheduled for a baseline interview at Dr. Elbogen's research office at Duke after a preliminary telephone screen. After providing informed consent, participants will complete an eligibility assessment, a physical function test, self-report questionnaire on pain interference including clinical interviews for health outcomes of pain; self-report questionnaire on pain interference, pain self-efficacy, drug and alcohol use, opioid use, drug/alcohol use; a physical function test; and an EEG. Participants will be be randomly assigned to either an experimental (mobile neurofeedback) or placebo-control (sham neurofeedback) group. All participants will receive a portable Muse EEG headset and an iPod Touch with a mobile app named 'Mobile Neurofeedback' and be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo). Study coordinators will conduct 6 check in calls in the intervening period, the study team will to reinforce training, troubleshoot technical problems, and assess any risk/safety issues (weeks 1,3,5,7,9, and 11). Follow-up data will be collected upon completion of the intervention at 12 weeks, 24 weeks and 36 weeks. During all follow-up visits, participants will complete self-report questionnaires, a physical function test, and an EEG. Data will be collected at baseline, 3, 6, and 9 months.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

Keywords

  • Neurofeedback
  • Biofeedback
  • Mobile Device
  • chronic low back pain
  • Pain Intensity
  • Relaxation
  • mHealth
  • Opioid
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Responding greater than 3 months to "How long has low back pain been an ongoing problem for you?"
  2. Responding 'at least half the days' to "How often has low back pain been an ongoing problem for you over the past 6 months?"

Investigators will follow recommendations to items and responses provided by the NIH Task Force on Research Standards for Chronic Low Back Pain, which specifically: "recommended 2 questions to achieve the definition of chronic low back pain: (1) How long has back pain been an ongoing problem for you? (2) How often has low back pain been an ongoing problem for you over the past 6 months? A response of greater than 3 months to question 1 and a response of 'at least half the days in the past 6 months' to question 2 would define chronic lower back pain."

Exclusion criteria

Exclusion Criteria:

  1. History of seizures.
  2. Planning pain-related surgery in the next 9 months.
  3. Individuals with implanted medical devices that could experience interference during EEG and/or , such as a spinal cord stimulator or pacemaker.
  4. Lower back pain is associated with compensation or litigation issues.
  5. Rating of past week pain intensity\<4 on 0-10 point scale.
  6. Rating of past week pain interference\<4 on 0-10 point scale.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Experimental Condition

    Mobile Neurofeedback intervention arm

    Device: Neurofeedback

  • Placebo comparator
    Control Condition

    Sham-control arm

    Device: Sham (Placebo Control)

Interventions

  • DeviceNeurofeedback

    Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.

  • DeviceSham (Placebo Control)

    Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).

06

What researchers measure

Primary outcomes

  1. Change in pain intensity

    Low back pain intensity on a 0-10 point rating scale, where higher scores indicate greater pain intensity.

    Time frame: Months 3, 6, and 9

Secondary outcomes

  1. Change in pain interference as measured by PROMIS (Patient-Reported Outcomes Measurement Information System)

    A higher PROMIS T-score indicates greater pain interference. The minimum score is 8 and the maximum score is 40.

    Time frame: Months 3, 6, and 9

  2. Change in physical function as measured by speed on the 50-foot walk test

    Participant is timed by how long it takes for them to walk 50 feet.

    Time frame: Months 3, 6, and 9

  3. Change in alpha brainwave (8 - 13 Hz) power as measured by EEG (electroencephalography)

    An EEG can identify and measure the electrical activity in the brain. Higher EEG alpha brainwave power indicates a greater state of relaxation.

    Time frame: Months 3, 6, and 9

07

Study locations

1 of 1 sites recruiting
  • Duke University Medical Center, Department of Psychiatry
    Durham, North Carolina 27705, United States
    Recruiting
    • Eric Elbogen · Contactvetstudy@duke.edu · 919-684-9983
    • Eric Elbogen, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for May 2027, 42 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 42 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Dec 30, 2022
StartActual
Oct 2, 2023
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669027
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Oct 2, 2023
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

Janequia Evans
Contact
DBHTL@duke.edu
919-681-1613
Eric Elbogen, Ph.D.
principal investigator · Duke - Professor in Psychiatry and Behavioral Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion